Arcapta

Drug - Arcapta (indacaterol) [Novartis]

June 2012

Therapeutic area - COPD

Approval criteria

• Patient has a diagnosis of COPD AND
• Patient has tried and failed 2 of the following 3 drugs used for maintenance treatment of COPD: Serevent, Foradil, Spiriva

Quantity limit

Quantity Limit = 30

Background information

ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411